Well, what about the CLIA waiver. The POC cancer test presumably won't need a waiver, and Dengue fever isn't much of an issue in the US (at least not yet, although there was an outbreak when I lived in Hawaii).
Another question: do they have enough research staff and research dollars to accomplish all these goals. If they're expanding staff, from where will the money come?
Yup. You don't just decide one day you're going to specialize in diagnostics. It's like the kid who gets car sick on the freeway saying they want to be an astronaut when they grow up.
Maybe, maybe not. Will have to wait for conference call. Also, the CLIA waiver worries persist.
Also going to have to disagree with you on that because Avi Pelossof, ALR's infectious disease chief, worked at CEMI for many years, and ALR has stated they intend to focus more on diagnostics in the future.
Well, their POC tests function on an antiquated platform. CEMI is really a platform company, not a diagnostics company. Alere has held lateral flow patent technology for many years now (soon expiring), and they are working on future technologies, but they don't have DPP, which CEMI is going to license far and wide.
If they get a CLIA waiver for DPP HIV and if they have an Ebola and multiplex with Ebola in the next few months.
My question: where is CEMI going to get the cash for all the Ebola work. I'm assuming government grants are forthcoming.
All that said, their bread and butter is DPP HIV, Syphilis, and HCV. Work in those areas must continue and the FDA must be reasonable on CLIA waivers for these products.
Mr. "protect the investment" (remember that LS classic) was a "dumb" seller under $4. I'd expect no less from the brilliant Larry Siebert.
Huh? I'm in the 99% when it comes to individual investors, and I'm a big investor in CEMI. My approach is always to battle test my ideas but making my concerns public.